James George Chopas insider trades: Apellis Pharmaceuticals (APLS) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where James reports to the SEC
Open-market buys and sales
17 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jan 22, 2026 | APLS | ↓ Sell | 2,064 | $21.77 | $45K | Direct | Jan 23, 2026 (1d) |
| Jan 20, 2026 | APLS | ↓ Sell | 726 | $19.79 | $14K | Direct | Jan 21, 2026 (1d) |
| Jan 13, 2026 | APLS | ↓ Sell | 873 | $22.19 | $19K | Direct | Jan 15, 2026 (2d) |
| Sep 15, 2025 | APLS | ↓ Sell | 189 | $24.19 | $5K | Direct | Sep 17, 2025 (2d) |
| Sep 2, 2025 | APLS | ↓ Sell | 548 | $28.08 | $15K | Direct | Sep 3, 2025 (1d) |
| Mar 17, 2025 | APLS | ↓ Sell | 183 | $24.82 | $5K | Direct | Mar 18, 2025 (1d) |
| Jan 22, 2025 | APLS | ↓ Sell | 1,096 | $30.43 | $33K | Direct | Jan 23, 2025 (1d) |
| Jan 17, 2025 | APLS | ↓ Sell | 715 | $29.96 | $21K | Direct | Jan 21, 2025 (4d) |
| Jan 13, 2025 | APLS | ↓ Sell | 783 | $28.70 | $22K | Direct | Jan 14, 2025 (1d) |
| Sep 16, 2024 | APLS | ↓ Sell | 192 | $36.21 | $7K | Direct | Sep 17, 2024 (1d) |
| Sep 3, 2024 | APLS | ↓ Sell | 550 | $39.49 | $22K | Direct | Sep 4, 2024 (1d) |
| Mar 15, 2024 | APLS | ↓ Sell | 184 | $56.46 | $10K | Direct | Mar 18, 2024 (3d) |
| Jan 22, 2024 | APLS | ↓ Sell | 1,061 | $65.00 | $69K | Direct | Jan 23, 2024 (1d) |
| Jan 16, 2024 | APLS | ↓ Sell | 864 | $66.81 | $58K | Direct | Jan 17, 2024 (1d) |
| Oct 23, 2023 | APLS | ↓ Sell | 132 | $46.04 | $6K | Direct | Oct 24, 2023 (1d) |
| Aug 31, 2023 | APLS | ↓ Sell | 551 | $41.23 | $23K | Direct | Sep 1, 2023 (1d) |
| Mar 5, 2021 | RDUS | ↓ Sell | 370 | $20.88 | $8K | Direct | Mar 9, 2021 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other APLS insiders
Open-market trades in the last 12 months
About James George Chopas's insider trades
James George Chopas is VP/Chief Accounting Officer at Apellis Pharmaceuticals (APLS). Since Mar 5, 2021, James has reported no open-market purchases and 17 sales worth $383K on SEC Form 4. In the last 12 months: 3 sales ($79K).
Their filings also include grants and awards (14 filings), shares withheld for taxes (4 filings), other transactions (1 filing), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every APLS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.